Consequently, GABA uptake inhibitors have emerged as potential therapeutic agents for these conditions, leading to increased interest in the development of new compounds that can effectively ...

Perhaps a grand unified theory will emerge whereby the three fundamental forces in schizophrenia research (NMDA, GABA and dopamine) all become united by the involvement of reactive oxygen species ...

Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” as a potential best-in-class next-generation GABA-AT ...

Oppenheimer has upgraded Ovid Therapeutics (NASDAQ:OVID) to outperform from perform, citing its drug candidate OV329. "While early, we believe OV329's promise is quite real as a potential ...